{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:38:26Z","timestamp":1789173506787,"version":"build-2803163510"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,3]],"date-time":"2019-03-03T00:00:00Z","timestamp":1551571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jare.2019.03.001","type":"journal-article","created":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T02:48:21Z","timestamp":1551926901000},"page":"43-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: The debate continues \u2013 A mini-review"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0816-9575","authenticated-orcid":false,"given":"Mohamed","family":"El Kassas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer","family":"Elbaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Salaheldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lobna","family":"Abdelsalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Kaseb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamal","family":"Esmat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jare.2019.03.001_b0005","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotype","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jare.2019.03.001_b0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/liv.13186","article-title":"The prevalence of hepatits C infection in Egypt 2015: implication for future policy on prevention and treatment","volume":"37","author":"Kandeel","year":"2017","journal-title":"Liver Int."},{"key":"10.1016\/j.jare.2019.03.001_b0015","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.cgh.2007.02.039","article-title":"Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis","volume":"5","author":"Ioannou","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jare.2019.03.001_b0020","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","article-title":"Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies","volume":"158","author":"Morgan","year":"2013","journal-title":"Ann. Int. Med."},{"key":"10.1016\/j.jare.2019.03.001_b0025","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/hep.510290439","article-title":"Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis","volume":"29","author":"Ikeda","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jare.2019.03.001_b0030","article-title":"Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"8[9]","author":"Zhuang","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jare.2019.03.001_b0035","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10620-014-3361-6","article-title":"Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin","volume":"60","author":"Moon","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.jare.2019.03.001_b0040","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/jvh.12854","article-title":"Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C-infected Egyptian cohort: a comparative analysis","volume":"25","author":"El Kassas","year":"2018","journal-title":"J. Viral. Hepat."},{"key":"10.1016\/j.jare.2019.03.001_b0045","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrgastro.2016.140","article-title":"Liver cancer: Effect of HCV clearance with direct-acting antiviral agents on HCC","volume":"13","author":"Llovet","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jare.2019.03.001_b0050","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jare.2019.03.001_b0055","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jhep.2016.04.033","article-title":"Direct antiviral agents and risk for HCC early recurrence: much ado about nothing","volume":"65","author":"Camm\u00e0","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jare.2019.03.001_b0060","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals","volume":"65","author":"Conti","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jare.2019.03.001_b0065","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jhep.2016.07.027","article-title":"High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis","volume":"65","author":"Cardoso","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jare.2019.03.001_b0070","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jhep.2016.06.009","article-title":"Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment","volume":"65","author":"Kozbial","year":"2016","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.jare.2019.03.001_b0075","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jhep.2017.11.011","article-title":"Rapidly growing, moderately differentiated HCC: a clinicopathological characteristic of HCC occurrence after IFN-free DAA therapy?","volume":"68","author":"Nakao","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jare.2019.03.001_b0080","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/jvh.12726","article-title":"The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: a Belgian experience","volume":"24","author":"Bielen","year":"2017","journal-title":"J. Viral. Hepat."},{"key":"10.1016\/j.jare.2019.03.001_b0085","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1159\/000480183","article-title":"Hepatocellular carcinoma after achievement of sustained viral response with daclatasvir and asunaprevir in patients with chronic hepatitis C virus infection","volume":"35","author":"Ida","year":"2017","journal-title":"Dig. Dis."},{"key":"10.1016\/j.jare.2019.03.001_b0090","first-page":"760A","article-title":"Hepatocellular carcinoma recurrence after curative treatments in patients with chronic hepatitis C who underwent direct-acting. Antiviral therapy","volume":"66","author":"Minami","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jare.2019.03.001_b0095","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/liv.13456","article-title":"Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C","volume":"37","author":"Virlogeux","year":"2017","journal-title":"Liver Int."},{"key":"10.1016\/j.jare.2019.03.001_b0100","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jhep.2017.07.007","article-title":"Hepatocellular carcinoma recurrence after direct antiviral agent treatment: a European multicentre study","volume":"67","author":"Kolly","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jare.2019.03.001_b0105","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s12664-017-0755-3","article-title":"Relationship of hepatitis B virus infection to the recurrence of hepatocellular carcinoma after direct acting antivirals","volume":"36","author":"Shimizu","year":"2017","journal-title":"Indian J. Gastroenterol."},{"key":"10.1016\/j.jare.2019.03.001_b0110","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jhep.2016.06.023","article-title":"Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma","volume":"65","author":"Yang","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jare.2019.03.001_b0115","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jhep.2017.05.028","article-title":"Liver Conference Study Group. Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C","volume":"67","author":"Nagata","year":"2017","journal-title":"J. Hepatol."},{"issue":"8","key":"10.1016\/j.jare.2019.03.001_b0120","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/MEG.0000000000001152","article-title":"Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact","volume":"30","author":"Hassany","year":"2018","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jare.2019.03.001_b0125","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/S0168-8278(17)30302-1","article-title":"PS-031- Tumour recurrence after Interferon-free treatment for hepatitis C in patients with previously treated hepatocellular carcinoma discloses a more aggressive pattern and faster tumour growth","volume":"66","author":"Reig","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jare.2019.03.001_b0130","first-page":"506","article-title":"Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis","volume":"28","author":"Renzulli","year":"2018","journal-title":"EurRadiol."},{"issue":"1","key":"10.1016\/j.jare.2019.03.001_b0135","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/MEG.0000000000001004","article-title":"De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus","volume":"30","author":"Abdelaziz","year":"2018","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jare.2019.03.001_b0140","article-title":"Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma","author":"Ioannou","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jare.2019.03.001_b0145","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jare.2019.03.001_b0150","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/j.gastro.2018.04.008","article-title":"Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents","volume":"155","author":"Calvaruso","year":"2018","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jare.2019.03.001_b0155","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jhep.2018.03.009","article-title":"Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study","volume":"69","author":"Romano","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jare.2019.03.001_b0160","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jhep.2017.03.032","article-title":"Occurrence of hepatocellular carcinoma in HIV\/HCV co-infected patients treated with direct-acting antivirals","volume":"67","author":"Hasson","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jare.2019.03.001_b0165","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jhep.2017.01.028","article-title":"Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: results from a Spanish real-world cohort","volume":"66","author":"Calleja","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jare.2019.03.001_b0170","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jhep.2016.08.016","article-title":"Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured?","volume":"66","author":"Zavaglia","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jare.2019.03.001_b0175","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2016.05.034","article-title":"Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment","volume":"65","author":"Torres","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jare.2019.03.001_b0180","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jhep.2016.07.029","article-title":"Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: too alarming?","volume":"65","author":"Zeng","year":"2016","journal-title":"J, Hepatol."},{"issue":"1","key":"10.1016\/j.jare.2019.03.001_b0185","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/apt.14380","article-title":"Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment","volume":"47","author":"Ogawa","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jare.2019.03.001_b0190","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/apt.14256","article-title":"Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study","volume":"46","author":"Cabibbo","year":"2017","journal-title":"Aliment Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.jare.2019.03.001_b0195","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","article-title":"Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis","volume":"65","author":"Cheung","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jare.2019.03.001_b0200","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jhep.2016.05.045","article-title":"collaborative study group on hepatocellular carcinoma [ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts]. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts","volume":"65","author":"ANRS","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jare.2019.03.001_b0205","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","article-title":"Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression","volume":"67","author":"Waziry","year":"2017","journal-title":"J. Hepatol."},{"issue":"suppl 1","key":"10.1016\/j.jare.2019.03.001_b0210","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/S0168-8278(18)30389-1","article-title":"HCC recurrence under all-oral DAAs-based antiviral therapy in HCV-infected patients: data from Navigatore web platform","volume":"68","author":"Gambato","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jare.2019.03.001_b0215","doi-asserted-by":"crossref","first-page":"e0179096","DOI":"10.1371\/journal.pone.0179096","article-title":"On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C","volume":"12","author":"Chu","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jare.2019.03.001_b0220","unstructured":"Unexpected Hepatocellular Carcinoma (HCC) following treatment\u2010induced HCV clearance in a VA cohort. Monto A, Ryan J, Niemi E, segal M, Lanier L. Hepatol. 2017;66:S1. 1412."},{"key":"10.1016\/j.jare.2019.03.001_b0225","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00535-014-0932-4","article-title":"Antitumor function of microRNA-122 against hepatocellular carcinoma","volume":"49","author":"Nakao","year":"2014","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jare.2019.03.001_b0230","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/jvh.12470","article-title":"Serum miR-122 may serve as a biomarker for response to direct acting antivirals: effect of paritaprevir\/R with dasabuvir or ombitasvir on miR-122 in HCV-infected subjects","volume":"23","author":"Waring","year":"2016","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jare.2019.03.001_b0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167934","article-title":"DAAs rapidly reduce inflammation but increase serum VEGF level: a rationale for tumor risk during anti-HCV treatment","volume":"11","author":"Villani","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jare.2019.03.001_b0240","doi-asserted-by":"crossref","unstructured":"Mettke F, Schlevogt B, Deterding K, Wranke A, Smith A, Port K, et al. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does notchange the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis. Aliment Pharmacol Ther 2018;47:516\u2013525.","DOI":"10.1111\/apt.14427"},{"key":"10.1016\/j.jare.2019.03.001_b0245","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1007\/s10620-017-4739-z","article-title":"Direct-acting antivirals decreased tumor recurrence after initial treatment of hepatitis C virus-related hepatocellular carcinoma","volume":"62","author":"Ikeda","year":"2017","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jare.2019.03.001_b0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194704","article-title":"Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group","volume":"13","author":"Mashiba","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jare.2019.03.001_b0255","first-page":"518A","article-title":"Long-term follow up of patients with chronic HCV and no or minimal fibrosis shows low risk for liver- related morbidity and mortality after achieving SVR with DAA based therapy: results from the Gilead SVR Registry","volume":"66","author":"Bourliere","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jare.2019.03.001_b0260","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/S0168-8278(17)30454-3","article-title":"LBP-509-Occurrence and recurrence of malignancies post DAA Treatment in 5.1% of patients-single center experience","volume":"66","author":"Issachar","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jare.2019.03.001_b0265","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/lt.24790","article-title":"Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals","volume":"23","author":"Zanetto","year":"2017","journal-title":"Liver Transpl."},{"key":"10.1016\/j.jare.2019.03.001_b0270","first-page":"46A","article-title":"Low rates of de novo or recurrent hepatocellular carcinoma in HCV cirrhotic patients treated with direct-acting antivirals (DAAs): a singlecenter experience","volume":"66","author":"Degasperi","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jare.2019.03.001_b0275","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/S0168-8278(17)30372-0","article-title":"PS-096-Long-term follow-up after IFN-free therapy of advanced HCV-associated liver cirrhosis: continued improvement of liver function parameters \u2013 results from the German Hepatitis C-Registry (DHC-R)","volume":"66","author":"Deterding","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jare.2019.03.001_b0280","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000470910","article-title":"Outcome of all-oral direct-acting antiviral regimens on the rate of development of hepatocellular carcinoma in patients with Hepatitis C virus genotype 1-related chronic liver disease","volume":"93","author":"Ogata","year":"2017","journal-title":"Oncology"},{"key":"10.1016\/j.jare.2019.03.001_b0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182710","article-title":"The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy","volume":"12","author":"Nagaoki","year":"2017","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.jare.2019.03.001_b0290","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2017.10.033","article-title":"The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen","volume":"68","author":"Innes","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jare.2019.03.001_b0295","first-page":"71A","article-title":"Continued increase in incidence of de novo hepatocellular carcinoma among liver transplant registrants with hepatitis C virus infection","volume":"66","author":"Kwong","year":"2017","journal-title":"Hepatology"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123219300669?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123219300669?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:46:50Z","timestamp":1761857210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2090123219300669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":59,"alternative-id":["S2090123219300669"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2019.03.001","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: The debate continues \u2013 A mini-review","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2019.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}